{"id":7715,"date":"2018-01-11T00:00:00","date_gmt":"2018-01-10T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2018\/01\/11\/investigadors-idibell-proven-amb-exit-una-nova-terapia-combinada-en-sarcomes\/"},"modified":"2020-05-13T19:46:36","modified_gmt":"2020-05-13T17:46:36","slug":"investigadors-idibell-proven-amb-exit-una-nova-terapia-combinada-en-sarcomes","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2018\/01\/investigadors-idibell-proven-amb-exit-una-nova-terapia-combinada-en-sarcomes\/","title":{"rendered":"Investigadors IDIBELL proven amb \u00e8xit una nova ter\u00e0pia combinada en sarcomes"},"content":{"rendered":"<p>Investigadors del grup de Sarcomes del programa Oncobell de l&#8217;Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) han provat amb \u00e8xit una nova ter\u00e0pia combinada en el tractament d\u2019aquest tipus de tumor agressiu, poc freq\u00fcent, que afecta a nens i adults. Els resultats de l\u2019assaig cl\u00ednic, publicats a <em>Targeted Oncology<\/em>, suposen un \u00e8xit en l\u2019estrat\u00e8gia de recerca translacional liderada pel Dr. \u00d2scar Mart\u00ednez-Tirado, cap del grup, a la part b\u00e0sica, i el Dr. Xavier Garcia del Muro a la part cl\u00ednica.<\/p>\n<p>El tractament posat a prova combina dues estrat\u00e8gies terap\u00e8utiques: la gemcitabina, una quimioter\u00e0pia convencional ja emprada habitualment en el tractament de sarcomes, i sirolimus, un f\u00e0rmac immunosupressor dirigit de nova generaci\u00f3. \u201cLa gemcitabina \u00e9s un tractament amb un bon grau de toler\u00e0ncia, fet que el converteix en un molt bon candidat per a ter\u00e0pies combinades\u201d, explica el doctor Xavier Garcia del Muro, autor principal de l\u2019estudi.<\/p>\n<p>En l\u2019estudi, realitzat a vuit hospitals espanyols i coordinat per ICO-IDIBELL, van participar 28 pacients. Despr\u00e9s de rebre el tractament, la taxa de pacients lliures de progressi\u00f3 als 3 mesos \u2013 un par\u00e0metre habitualment emprat en aquest tipus d\u2019estudis &#8211; era del 44%, fet que confirma l\u2019efectivitat d\u2019aquesta nova ter\u00e0pia combinada.<\/p>\n<p>\u201cConsiderem que els resultats s\u00f3n positius i que per tant el tractament mereix seguir essent avaluat en estudis posteriors\u201d, afegeix Garcia del Muro.<\/p>\n<p>\u201cTamb\u00e9 val la pena destacar el marcat car\u00e0cter translacional de l\u2019estudi; hem partit del laboratori per arribar a la cl\u00ednica\u201d, comenta l\u2019investigador. Inicialment, el grup de recerca en sarcomes del Dr. Mart\u00ednez-Tirado va estudiar l\u2019efectivitat del tractament en l\u00ednies cel\u00b7lulars i model animal de ratol\u00ed, obtenint resultats molt prometedors. El posterior assaig cl\u00ednic de fase I va permetre determinar els par\u00e0metres de dosificaci\u00f3 i seguretat del tractament combinat, que s\u2019han emprat en el nou assaig per tal de valorar l\u2019efectivitat del tractament en humans.<\/p>\n<p>Els investigadors del programa Oncobell seguiran treballant en nous assajos cl\u00ednics per continuar explorant aquesta nova l\u00ednia terap\u00e8utica amb la finalitat de fer-la arribar a la pr\u00e0ctica cl\u00ednica tan aviat com sigui possible.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Investigadors del grup de Sarcomes del programa Oncobell de l&#8217;Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) han provat amb \u00e8xit una nova ter\u00e0pia combinada en el tractament d\u2019aquest tipus de tumor agressiu, poc freq\u00fcent, que afecta a nens i adults. Els resultats de l\u2019assaig cl\u00ednic, publicats a Targeted Oncology, suposen un \u00e8xit en l\u2019estrat\u00e8gia de recerca [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7716,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-11 02:42:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7715"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7715"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7715\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/7716"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}